An engineered protein turns off the kind of immune cells most likely to damage tissue as part of type 1 diabetes, hepatitis ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

AbbVie (ABBV) on Monday announced that it has entered into a definitive agreement to acquire privately held clinical-stage ...

ARGX-119 in congenital myasthenic syndromes: Amsterdam, the Netherlands Tuesday, July 1, 2025, 18:00 Hrs [IST] argenx SE, a global immunolo ...

Autoimmune disorders occur when the immune system mistakenly attacks the body's own tissues, leading to chronic conditions such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis ... the ...

Introduction Multiple sclerosis (MS) is a disease affecting the central nervous system (CNS), with inflammation and demyelination of nerves, eventually resulting in nerve damage and disabilities. MS ...

While there is currently no cure for multiple sclerosis, researchers continue to discover clues to give a better ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Anti-CD20 therapies, a type of MS treatment, changes levels and profiles of several immune cells in people with MS, a study ...

A study of twins reveals two gut bacteria linked to multiple sclerosis, offering new targets for future treatments.

Scientific research is at the heart of Israel’s success and has worldwide benefits. Our work will continue despite adversity.

Stem cell therapies offer emerging hope for systemic sclerosis, with autologous and mesenchymal options under investigation ...